NCT06008366View on ClinicalTrials.gov

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

February 1, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

7MW3711 for injection

IV administration of 7MW3711, Q3W, 3 weeks a cycle

DRUG

7MW3711 for injection

IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1

Trial Locations (1)

200032

RECRUITING

Ethics Committee of Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY